Pick of the day
Soufflé Therapeutics
A Watertown, Massachusetts biotech co-founded by MIT's Robert Langer that is building RNA medicines designed to reach muscle and heart tissue, not just the liver.
- Problem
- 8
- Traction
- 7
- Founders
- 9
- Market
- 8
- Novelty
- 7
Why today
Today's pick is Soufflé Therapeutics, the Watertown, Massachusetts RNA medicines company that closed a 135 million dollar Series B on October 14, 2026, led by Juvia Group. The window also included a 200 million dollar Series D for 3D-printing construction robotics company ICON at a 1.4 billion dollar valuation, a 34 million dollar round for Tel Aviv AI-workspace security startup Pluto Security, a 90 million dollar Series B for open-source AI agent maker Nous Research, and the stealth exit of deep-tech manufacturer Atomic Machines with 250 million dollars raised to date. Soufflé stands out because it is tackling a problem that has stalled the entire siRNA drug class: almost every approved or late-stage RNA therapy only reaches the liver, and co-founder Robert Langer's track record plus more than 3.5 billion dollars in big pharma partnerships already signal that major drugmakers are betting the company can crack delivery to muscle and heart tissue before a single program has entered the clinic.
Problem
Small interfering RNA drugs silence disease-causing genes by degrading their messenger RNA, but delivering siRNA anywhere outside the liver has remained the field's central unsolved problem. Approved siRNA medicines and most late-stage programs rely on GalNAc-sugar conjugates or lipid nanoparticles that naturally accumulate in liver cells, leaving diseases rooted in muscle, heart and other tissues without a practical RNA-based treatment option. That gap matters because many serious genetic diseases, including muscular dystrophies and inherited forms of heart failure, originate in exactly the tissues current RNA-delivery chemistry cannot reach, so the underlying biology is often validated years before any way to deliver a drug to it exists.
Product
Soufflé Therapeutics builds a delivery platform that pairs ligand discovery with receptor targeting, engineering siRNA molecules to bind receptors expressed on specific non-liver cell types so the drug is taken up by those cells rather than defaulting to the liver. The approach is designed to be modular: once a receptor unique to a target tissue is identified, the same chemistry can in principle be paired with different siRNA payloads to silence different disease genes in that tissue. The company's disclosed lead programs apply this to striated muscle and heart cells, with a third, undisclosed program aimed at additional muscle and metabolic disorders.
Traction
Soufflé has not yet put a program into the clinic, so it has no efficacy data in patients. What it does have is unusually heavy validation from the pharmaceutical industry: the company says it has secured more than 3.5 billion dollars combined in fundraising and partnership deals, including a January 2026 collaboration with Bayer to co-develop a cell-specific, heart-targeted siRNA therapy for dilated cardiomyopathy, plus earlier partnerships involving AbbVie, Amgen and Novo Nordisk. That scale of big-pharma commitment before any clinical data is a company-reported signal of confidence in the platform, not an independently verified efficacy result, and the company plans to enter the clinic in 2026.
Team
Soufflé was co-founded by Robert Langer, the MIT Institute Professor whose lab has spun out dozens of biotech companies and who co-founded Moderna, alongside MIT scientists Daniel Anderson and Brad Pentelute and former Alnylam scientist Victor Kotelianski. Langer's daughter, Susan Langer, is founding president and chief business officer. The company is led by CEO Amir Nashat, a PhD chemical engineer who was previously a managing partner at Polaris Partners and CEO of Dewpoint Therapeutics and Paratus Sciences. That pairing of a landmark academic founder with an operator CEO who has venture and biotech-leadership experience is a big part of why big pharma signed on before any trial data existed.
Funding
The 135 million dollar Series B, announced October 14, 2026, was led by Juvia Group, with TCG Crossover, BB Biotech, Fidelity Management and Research, Balyasny Asset Management and Amgen Ventures also participating in an oversubscribed round. It follows a roughly 200 million dollar Series A in 2025 that brought Soufflé out of stealth after it had operated quietly since 2021. The company has not disclosed a valuation for either round. Proceeds are earmarked for pushing its lead muscle and heart programs into clinical studies and continuing to expand the platform into additional cell types and tissues beyond the three disclosed programs.
Competitors
Soufflé is entering a field where delivering RNA drugs outside the liver is already a declared priority for larger, better-funded rivals. Alnylam, the field's leader, has said in SEC filings that it is advancing extrahepatic conjugate approaches aimed at muscle and adipose tissue. Avidity Biosciences, now part of Novartis, names Alnylam, Dyne, Ionis, Sarepta, PepGen and Entrada among its own competitors for skeletal and cardiac muscle delivery using antibody-oligonucleotide conjugates, a different chemistry than Soufflé's receptor-targeting approach. None of these rivals has yet brought an extrahepatic siRNA drug to approval, so the race remains open on delivery chemistry rather than on clinical proof.
VC lens
Would YC fund it? Yes, though less for the usual reasons: Soufflé already has blue-chip pharma partners and a founder in Robert Langer with one of biotech's strongest track records, so the real test is whether its receptor-targeting chemistry proves out in the clinic starting in 2026, not whether it can raise money or sign deals.
Biggest risk: Every claim about Soufflé's platform, including the 3.5 billion dollar partnership figure, is company-reported and predates any clinical data; if the receptor-targeting approach fails to safely and effectively silence genes in muscle or heart tissue once programs reach patients, the big pharma deals and the premium built on them could unwind quickly.
Runners-up
ICON
200 million dollar Series D co-led by Baillie Gifford and BlackRock funds at a 1.4 billion dollar valuation, for the Austin-based company scaling its Titan robotic system for 3D-printed construction. (Oct 13)
Pluto Security
34 million dollar funding round led by Jump Capital, bringing total funding to about 42 million dollars, for the Tel Aviv startup securing the AI tools and apps employees build themselves, which reached 2 million dollars in annualized revenue within months of launching sales. (Oct 13)
Nous Research
90 million dollar Series B led by Robot Ventures at a reported 1.5 billion dollar valuation, for the open-source AI agent startup launching an enterprise version of its Hermes agent after reporting roughly 36 million dollars in annualized revenue. (Oct 7)
Atomic Machines
250 million dollars raised to date as the Emeryville, California company exited six years of stealth with its Matter Compiler system for building micro-machines from code, starting with a power relay aimed at AI data centers. (Oct 7)
Archive
38 reports · click a row to open it| Date | Winner | One-liner | Runners-up | Open |
|---|---|---|---|---|
| 2026-10-19 | Modal Labs | 750 million dollar Series D led by Accel at a 15.75 billion dollar valuation, as the AI infrastructure startup says its annualized run rate crossed 1 billion dollars with usage tripling in five months, built on serverless GPU access for inference, training and agent sandboxes | OMass Therapeutics, Scanntech, North.cloud, Fortem Technologies | |
| 2026-10-18 | Mueon | 65 million dollar Series A led by Maverick Silicon, as the Portland semiconductor startup founded by two Intel veterans scales Cubelets, modular 3D blocks bundling compute, memory, power and cooling to cut AI data center power and density limits, already in use by AI chip startup d-Matrix | Estuary Biotherapeutics, Fission, Otter Health, HyLight | |
| 2026-10-17 | Chariot Claims | 10 million dollar Series A led by Silverton Partners, as the rebranded ClaimClam legal-tech platform scales automated matching of consumers to mass arbitration and class-action claims over hidden fees and hard-to-cancel subscriptions, building on more than 65,000 claims already processed toward an estimated 92 million dollars in settlements | Marklo, Siena, Rein Security, Peppermint | |
| 2026-10-16 | Salience Labs | 125 million dollar oversubscribed Series B led by Bullhound Capital, as the Oxford-spun-out photonics company wins new backing from AMD Ventures and Intel Capital for all-optical circuit switches meant to break the power and latency ceiling facing electronic switches as AI GPU clusters scale toward tens of thousands of chips | Navra, Type One Energy, Oratomic, Gallatin AI | |
| 2026-10-15 | Soufflé Therapeutics | 135 million dollar Series B led by Juvia Group, as the MIT bioengineer Robert Langer-founded biotech works to deliver RNA medicines to muscle and heart tissue, a problem that has stalled the entire siRNA drug class, backed by more than 3.5 billion dollars in big pharma partnerships before any program has reached the clinic | ICON, Pluto Security, Nous Research, Atomic Machines | |
| 2026-10-14 | Vitalize | 31 million dollar Series A led by Oak HC and FT, as the Y Combinator-backed startup unifying hospital staffing, scheduling, patient flow and capacity management expands after enterprise customers reported cutting manual scheduling work and premium labor spend | Gallatin AI, byteXL, Desible.ai, Credfix | |
| 2026-10-13 | Universal Quantum | 100 million dollar Series A co-led by DCVC and Firgun Ventures, a record raise for a UK quantum computing company, as the University of Sussex spinout races to prove its modular trapped-ion chiplet interconnect can out-scale newly public rivals Quantinuum and IonQ | Atlas Atomics, Type One Energy, Sabi, Catalyst | |
| 2026-10-12 | Manus | 500 million dollar funding round led by Boyu Capital and IDG Capital, the general AI agent's first raise since China blocked Meta's 2 billion dollar bid for the company and barred its founders from leaving the country, as Manus pursues a reported 4 billion dollar valuation on roughly 125 million dollars of annualized revenue | Oratomic, Matchpoint Therapeutics, Oxide Computer, Stuut | |
| 2026-10-11 | Arena | 200 million dollar Series B co-led by Lightspeed Venture Partners and Khosla Ventures at a 3.1 billion dollar valuation, as the company behind the Chatbot Arena leaderboard nearly doubles its valuation in ten months on roughly 100 million dollars of annualized revenue from selling AI evaluation and alignment benchmarking to labs and enterprises, while Scale AI's new Seal Showdown contests its neutral-referee position | Gallatin AI, Rein Security, Rivercell, TeddyHoldings.AI | |
| 2026-10-10 | Multiply Labs | 75 million dollar Series B led by Patrick Soon-Shiong's NantWorks with new investors AstraZeneca, Lingotto, Teradyne and Strange Ventures, as the decade-old biologics-manufacturing robotics company passes 100 million dollars raised on the strength of its first commercial sale, an up to 85 million dollar deal with Retro Biosciences, while competing against well-funded rivals Cellares and Ori Biotech to automate cell and gene therapy production | Zomint, Parakeet Health, OuterSignal, Efficient Computer | |
| 2026-10-09 | RougeTx | 58 million dollar Series A led by BioGeneration Ventures and Angelini Ventures with the European Investment Bank's Aurea facility and Kurma Partners also investing, as the Leiden University Medical Center spinout launches the first disease-modifying candidate for hereditary hemorrhagic telangiectasia, a bleeding disorder with no approved therapies, built on more than two decades of pericyte research | GMI Cloud, Varda Space Industries, doxx.net, Beyond Appliances | |
| 2026-10-08 | General Medicine | 120 million dollar Series B led by Andreessen Horowitz with Eli Lilly and Mercy Health joining, as the PillPack founders' online healthcare marketplace brings total funding to 152 million dollars less than three years after launch on hundreds of thousands of customers and an 80 Net Promoter Score | Noah, Nous Research, Buntar Aerospace, Monid | |
| 2026-10-07 | Vinci | 250 million dollar Series B at a 1.5 billion dollar valuation co-led by Advent, Temasek and Xora Innovation, as the Palo Alto physics foundation model startup jumps from a 46 million dollar seed and Series A disclosed last December to a tenfold valuation leap less than a year later, aiming its technology at chip design incumbents Cadence and Synopsys | Spiko, Hadrian, WhiteLab Genomics, Inbolt | |
| 2026-10-06 | Pandektes | 13.5 million euro Series A led by Munich's Alstin Capital, as the Copenhagen legal-research startup grows revenue sixfold and wins customers switching off LexisNexis, Westlaw, Beck and Karnov with an API-first legal data platform | OneByZero, Fleuret AI, Laki Power, RobCo | |
| 2026-10-05 | PaleBlueDot AI | 200 million dollar Series C at a 3.2 billion dollar valuation led by ComputeCore, as the Palo Alto AI compute platform nearly triples its valuation in under nine months on more than 5 billion dollars of signed customer contracts | Simple Energy, Elio Mortgage, Menos AI, SedMed | |
| 2026-10-04 | Flow Engineering | 50 million dollar Series B at a 750 million dollar valuation co-led by Valor Equity Partners and Atreides Management, as the AI-native systems-engineering platform for hardware teams grows to over 100 million requirements managed and adds General Motors, Anduril and Intuitive Machines as customers less than a year after its Series A | Miter, Kanu AI, Beltic, Satlyt | |
| 2026-10-03 | EliseAI | 350 million dollar round at a 4 billion dollar valuation led by Andreessen Horowitz and Bessemer Venture Partners, as the housing and healthcare conversational AI company nearly doubles its valuation in thirteen months on 200 million dollars of ARR and five straight years of 100 percent revenue growth | Kahua, Breye Therapeutics, Amara, Kuro | |
| 2026-10-02 | Armadin | 255.5 million dollar Series B co-led by Andreessen Horowitz and Accel at a 2.5 billion dollar valuation, as Mandiant founder Kevin Mandia's agentic attacker-swarm security platform runs live attack campaigns for Fortune 500 and government customers seven months after stealth | Foundational, Seeds Fincap, Numeral, Chamelio | |
| 2026-10-01 | General Intuition | 220 million dollar Series B at a 6.2 billion dollar valuation, nearly tripling in three months, as the AI foundation model startup trains action models on billions of gameplay clips from its own sister company Medal | Varda, Jeeves, Sand.ai, Arivihan | |
| 2026-09-30 | Tiny Health | Oversubscribed $33M Series B led by B Capital as the at-home microbiome testing company posts 1,624% three-year revenue growth and quadruples its practitioner-facing business | Modulate, erad, Baselayer, Ande | |
| 2026-09-29 | Instinct | $1B Series C led by Sequoia, Benchmark and Coatue at a $10B valuation, a roughly 4x jump in five weeks, as its text-message AI agent passes 100,000 users with 10% daily compounding growth | SiMa.ai, Quartermaster, Outmarket AI, Humanos | |
| 2026-09-28 | Solcoa Industries | $75M seed ($45M equity led by Bain Capital Ventures plus $30M JPMorgan-anchored debt) to build a 500-tonne Nevada plant using a novel rare-earth metalmaking process, aimed at breaking China's 95% grip on metallization | Clastix, Prevision Medicine, Spiich, Barq | |
| 2026-09-27 | Ultraviolette | $85M Series E led by Yali Capital and TDK Ventures; Bengaluru performance EV motorcycle maker plans US entry by 2027 on 4-5x revenue growth | Micro1, Kasvu Therapeutics, HIFI, Dextr AI | |
| 2026-09-26 | Island | $400M Series F led by Evolution Equity Partners at a $6.4B valuation, more than doubling its 2024 valuation as the enterprise browser expands into governing AI agents | Cyera, Confido, Heidi Health, Firecrawl | |
| 2026-09-25 | Ema | $77M Series B led by Creaegis, more than quadrupling its valuation as every existing backer doubled down and Wipro scales its AI Employees to 240,000+ workers | Ando, Kasvu Therapeutics, HIFI, Nuvah | |
| 2026-09-24 | TEKEVER | $580M Series D led by UC Investments and Baillie Gifford; Ukraine-proven AI surveillance drone maker hits $6.4B valuation on a new 400M pound UK Army contract | Enveda Biosciences, Basecamp Research, Numeral, Brahma AI | |
| 2026-09-23 | Verda | $189M oversubscribed Series B led by Emergence Capital; profitable Nordic GPU cloud crosses $1B valuation on $165M ARR | Snorkel AI, Nexstrom, MacroCycle, Demoverse | |
| 2026-09-22 | BCI-Sonics | RMB 200M (~$30M) Pre-Series A led by HSG and Yunqi Capital; non-invasive ultrasound brain-computer interface racing China's invasive BCI leaders and OpenAI-backed Merge Labs | Spott, HighLife, CellPoint, Benford | |
| 2026-09-22 | Amber Electric | €49M Series E led by Morgan Stanley's 1GT; automates 50%+ of Australia's home batteries, expanding VPP software into Europe via E.ON | Corridor, Paymob, Unit1 Studio, Drivn | |
| 2026-09-18 | TypeSafe AI | $40M seed led by DCVC; "System One" model returns typed decisions for software, not chat — built by RLHF co-inventor Diogo Almeida | Space Epoch, Facilo, Treble Technologies, DheyaTech | |
| 2026-09-17 | Exein | $270M Series C at $1.7B valuation (30x in 2 yrs); kernel-level security layer for robots, drones and autonomous machines | Anew Labs, Delos Data, CADDi, AIUC | |
| 2026-09-16 | Euclyd | €200M+ Series A; Samsung-backed (investor + manufacturer) AI inference chip built to out-efficiency Nvidia, chaired by ex-ASML CEO | Profound, Flam, ENCOS, Nutshell Therapeutics | |
| 2026-09-15 | Fortaegis | $50M oversubscribed Series A; quantum-safe security rooted in silicon, chaired by Quantinuum founder Ilyas Khan | Qupital, Tandem Health, Atomarine, UniqYou | |
| 2026-09-11 | Positron AI | $875M Series C at $5B valuation; memory-first inference chips challenging Nvidia's HBM lock-in | The Boring Company, Mach Industries, Rogo Technologies, Swish | |
| 2026-09-10 | Cognition AI | $2B+ Series E at $48B valuation; Devin autonomous coding agent nears $900M run-rate | DigitalPaani, Algomatic Dynamics, Limetax, Fundly.ai | |
| 2026-09-09 | Bluecore Energy | Floating nuclear reactor barges for ports; $50M seed just 2 months after stealth launch | QNu Labs, ARC Ride, Circolife, Hope Care | |
| 2026-09-08 | Pixxel | $100M Series C, India's largest spacetech round; building orbital AI data centers | Nua, Navana.ai, GalaxEye, Atoms (Kalanick) | |
| 2026-09-07 | Medulance | GPS-dispatched ambulance network raises ₹24 Cr Series A-2 | Comet, Mokobara, Kit (Speakeasy), XDOF |
Sources
- Endpoints News — Soufflé gets $135M for three RNA medicines
- FinSMEs — Soufflé Therapeutics Raises $135M in Series B Funding
- Dealroom — Soufflé Therapeutics raises $135M Series B to take RNA therapies into the clinic
- Fierce Biotech — Langer family RNA biotech Soufflé rises with $200M and Big Pharma partners
- Bayer — Advancing Cell-Specific Heart-Targeted siRNA Therapy
- SEC — Avidity Biosciences Form 10-K FY2025
- Axios Pro — Construction tech startup Icon raises $200M
- TechCrunch — Pluto Security raises $42M as AI gives enterprise security teams a new headache
- Dealroom — Nous Research raises $90M at $1.5B valuation for open source AI
- Dealroom — Atomic Machines Exits Stealth With $250M to Build Machines From Code
Compiled from search results: article pages were unreachable from the publishing environment on this date, so every fact here was cross-checked against at least two independent reports.